ArticleScientific reports2026
D-mannose alleviates rotenone-induced PD mouse model through microbiota-gut-brain axis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Parkinson’s disease (PD) is the second most common neurological degenerative disease in the elderly. Disruption of gut-brain axis crosstalk has been shown to be associated with the pathogenesis of PD. Although drug treatments for PD have been in development for decades, there is currently no drug or therapy that can completely cure PD. Therefore, there is an urgent need to discover new drugs to develop effective PD treatment strategies. D-mannose is a natural, bioactive monosaccharide that is a popular nutritional and health-beneficial food supplement worldwide. However, whether it has a neuroprotective effect on PD is still unclear. C57BL6/J mice aged 8–9 weeks were orally administrated with rotenone solution once a day for four weeks and drinking D-mannose for the following 2 weeks. Fresh fecal pellets from each mouse were used for 16 S rRNA sequencing. We found that D-mannose treatment alleviated motor symptoms, gastrointestinal dysfunctions in rotenone-induced PD mice. 16 S rRNA sequencing found that microbiota alterations were reversed by D-mannose in rotenone-induced PD mice. D-mannose treatment suppressed neuroinflammation by TLR4/MyD88/NF-κB pathway in the SN. This study proved that the importance of D-mannose on PD, and explored the potential mechanism of gut-brain axis in PD pathogenesis, providing a new target for clinical treatment of PD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.